IAG Partners with BMC/BUSM
London, UK and Boston, MA - Image Analysis Group (IAG) announced today that they have partnered with a new CRO spun out by BMC/BUSM Radiology to provide life sciences, biotech, medical device and pharmaceutical clients with expert clinical research services in imaging.
This partnership will offer IAG’s proprietary cloud-based platform Dynamika for clinical trial data management, patented advanced image analysis algorithms for imaging data analysis, and renowned scientific and analytical expertise of the radiologists to conduct global clinical trials.
The partnership will allow for BMC/BUSM Radiology to market IAG’s industry leading cloud based software platform for clinical trial data management and image analysis DYNAMIKA while IAG’s’ clients will benefit from BMC/BUSM radiology and clinical services expertise in oncology, immune-oncology, neuro-oncology, neurology and inflammation. The new partners will work in tandem to provide trial and endpoint design, trial management, site selection and management, project management, technical expert and radiology services globally.
“We believe that the combination of the technology platform, algorithms and services and with BMC Radiology’s medical depth creates a clinical trial imaging management team unrivalled in the industry”, commended Dr. Olga Kubassova, CEO of Image Analysis Group.
“We are pleased to gain a partner with such complementary skills and look forward to working together,” added the president of Boston Radiology Associates, Dr. Jorge Soto.
About Image Analysis Group
Image Analysis Group is an expert clinical research organization, delivering systems, scientific expertise and full service to support efficient design and execution of clinical trials, where imaging provides critical evidence of the novel compound safety and efficacy.
About BMC/BUSM Radiology
Boston Medical Center Radiology is a group of academic radiologists with research expertise and extensive clinical trials experience in all specialties including oncology, neuro-oncology, trauma etc. Members of the department have recognized proficiency in clinical trials design, execution and management.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
